First Results from Lexaria Bioscience Corp. (NASDAQ: LEXX) Study Show Marked Gains in Blood Pressure Reduction over Generic CBD Controls

August 6, 2021 09:54:43
  • Drug delivery platform developer Lexaria Bioscience has developed its patented DehydraTECH(TM) as a means of transforming pharmaceuticals that increases their bioavailability and speed of efficacy
  • Ongoing testing of DehydraTECH in combination with cannabidiol (“CBD”) is analyzing DehydraTECH’s responsiveness to hypertension conditions that are targeted in heart disease and stroke therapies
  • Partial results from the company’s first study indicate Lexaria’s DehydraTECH platform, when processed with CBD, reduces blood pressure and does so much more rapidly when compared with the generic CBD controls
  • The complete results of the study will be produced as sample and data analyses work are completed
  • Lexaria is already under way on a second study that examines the efficacy of DehydraTECH-enabled CBD in repeat dosing, and the company anticipates positive outcomes based on the partial results of the first study that were just released
Ongoing clinical studies of the DehydraTECH platform’s ability to render therapeutic drugs into a powder or liquid form that increases their ability to be rapidly absorbed by the body without adverse changes to the original substances have yielded important new findings on the blood pressure and heart disease fronts. Bioavailability technology innovator Lexaria Bioscience (NASDAQ: LEXX)  announced partial results from its human clinical study HYPER-H21-1 on July 29, which is evaluating cannabidiol (“CBD”) processed… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado 303.498.7722 Office CBDWire is part of the InvestorBrandNetwork.